Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
LOS ANGELES, Oct. 18, 2017 -- Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Teva Pharmaceutical Industries Limited (“Teva” or the “Company”) (NYSE:TEVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company’s shares between November 15, 2016 and August 2, 2017, inclusive (the “Class Period”), are encouraged to contact the firm before October 23, 2017, the lead plaintiff motion deadline.
If you are a shareholder who suffered a loss during the Class Period, click here to participate.
We also encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm’s website at http://www.goldberglawpc.com/, or by email at [email protected].
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Complaint alleges that throughout the Class Period, Teva issued materially false and/or misleading statements, and/or failed to disclose, that the poor performance of its U.S. generics business resulted in the Company recording a goodwill impairment charge related to the acquisition of Actavis Generics and was a key factor in cutting Teva’s dividend by 75%. When this news was announced, Teva’s stock price fell materially, which caused investors harm.
Goldberg Law PC represents investors around the world, and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Contact:
Goldberg Law PC, Los Angeles
Michael Goldberg, Esq., 800-977-7401
Brian Schall, Esq., 800-977-7401
[email protected]
www.Goldberglawpc.com
